Objectives: To observe the efficacy and safety of oxycodone hydrochloride prolonged-release tablets in the titration of moderate and severe cancer pain. Methods: 80 outpatients with moderate and severe cancer pain treated with oxycodone hydrochloride prolonged-release tablets were divided into two groups: experimental group used oxycodone hydrochloride prolonged-release tablets per 12h to start titration, control group used oxycodone hydrochloride prolonged-release tablets per 24h to start titration. The effects and adverse effects of two group within 24 hours and 72 hours were observed and compared. Results: After 24hours of titration, pain-relieving objective response rate of experimental group was 75.00%, while control group was 52.50% with statistically significant differences (p<0.05). After 72 hours of titration, the efficiency was 90.00% in experimental group and 87.50% in control group, and the difference was no statistically significant (p>0.05). The main adverse reactions of cancer pain patients were constipation, nausea and vomiting, abdominal distension, drowsiness, dizziness and anorexia apocleisis, and the symptoms all can be tolerated after symptomatic treatment. Conclusions: Oxycodone hydrochloride prolonged- release tablets per 12h to start titration are effective, convenient and rapid in titration of moderate and severe cancer pain.
| Published in | Asia-Pacific Journal of Medicine (Volume 2, Issue 4) |
| Page(s) | 28-31 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2019. Published by Science Publishing Group |
Cancer Pain, Titration, Oxycodone Hydrochloride Prolonged-release Tablet
| [1] | Wanqing C, Rongshou Z, Jie H, et al. Cancer Statistics in china, 2015 [J]. CA Cancer J Clin, 2016, 66: 115-132. |
| [2] | Deandrea S, Montanari M, Moja L, et al. Prevalence of under treatment in cancer pain. A review of published literature [J]. Ann Oncol, 2008, 19(12): 1985-1991. |
| [3] | 毛志兴, 陈月梅. 奥施康定治疗中重度癌痛的效果及其对患者生活质量和免疫功能的影响［J］.中外医学研究, 2017,15(19):8-10. |
| [4] | Bethann S, Cardinale S. Optimal pain management for patients with cancer in the modern era ［J］. CA Cancer J Clin, 2018,68: 182-196. |
| [5] | 刘勇，宋正波，梁军，等。羟考酮缓释片和吗啡即释片在中重度癌痛滴定中疗效及安全性比较的Meta分析［J］.临床肿瘤学杂志, 2016,21(07):585-592. |
| [6] | Eisenberg E MF, Birkhahn J, et al. Time to modify the WHO analgesic ladder. Pain Clinical Update ［J］, 2005: 1-4. |
| [7] | 张颖一，韩廷，汪颖，等。羟考酮控释片用于滴定中重度癌痛的疗效观察［J］.医学研究杂志，2011,40(4):52-54. |
| [8] | Fallon M, Giusti R, Hoskin P, et al. management of cancer pain in adult patients: ESMO clinical practice guidelines [J]. Ann Oncol, 2018, 29 (4): 166-191. |
| [9] | 王薇，李萍萍，樊碧发，等。北京市癌症疼痛管理规范(2017年版)［J］.中国疼痛医学杂志, 2017,23(12):881-889. |
| [10] | Riley J, Branford R, Droney J, et al. Morphine or oxycodone for cancer-related pain? A randomized, open-label, controlled trial [J]. J Pain Symptom Manage, 2015, 49(2): 161-72. |
| [11] | 原凌燕, 柳珂, 王湛, 等. 羟考酮控释片作为止痛背景用药在中重度癌痛滴定中的临床观察 ［J］. 临床肿瘤学杂志, 2015,20(08):722-725. |
| [12] | 鲍启德，杨兰兰，孙李凌，等。奥施康定滴定治疗中重度癌痛的临床研究［J］.河南医学研究, 2017,26(01):19-21. |
| [13] | 龚黎燕，孔祥鸣，裘友好，等。盐酸羟考酮缓释片联合吗啡片滴定中重度癌痛的临床观察［J］.中国疼痛医学杂志，2014,20(07):481-485. |
| [14] | 王延涛，王永顺。奥施康定剂量滴定治疗中重度癌痛的临床研究［J］.北方药学, 2013, 8:90-91. |
| [15] | Samolsky Dekel BC, Tomasi M, Vasarri A, et al. Opioid titration with sustained-release oxycodone and immediate-release morphine for moderate/severe cancer pain: a pilot assessment of the CoDem protocol [J]. J Opioid Manag, 2014, 10 (1): 29-38. |
APA Style
Guo Hui, Xu Huiqing. (2019). A Clinical Study of Oxycodone Hydrochloride Prolonged-release Tablets in the Titration of Cancer Pain. Asia-Pacific Journal of Medicine, 2(4), 28-31.
ACS Style
Guo Hui; Xu Huiqing. A Clinical Study of Oxycodone Hydrochloride Prolonged-release Tablets in the Titration of Cancer Pain. Asia-Pac. J. Med. 2019, 2(4), 28-31.
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10043464,
author = {Guo Hui and Xu Huiqing},
title = {A Clinical Study of Oxycodone Hydrochloride Prolonged-release Tablets in the Titration of Cancer Pain},
journal = {Asia-Pacific Journal of Medicine},
volume = {2},
number = {4},
pages = {28-31},
url = {https://www.sciencepublishinggroup.com/article/10043464},
abstract = {Objectives: To observe the efficacy and safety of oxycodone hydrochloride prolonged-release tablets in the titration of moderate and severe cancer pain. Methods: 80 outpatients with moderate and severe cancer pain treated with oxycodone hydrochloride prolonged-release tablets were divided into two groups: experimental group used oxycodone hydrochloride prolonged-release tablets per 12h to start titration, control group used oxycodone hydrochloride prolonged-release tablets per 24h to start titration. The effects and adverse effects of two group within 24 hours and 72 hours were observed and compared. Results: After 24hours of titration, pain-relieving objective response rate of experimental group was 75.00%, while control group was 52.50% with statistically significant differences (pp>0.05). The main adverse reactions of cancer pain patients were constipation, nausea and vomiting, abdominal distension, drowsiness, dizziness and anorexia apocleisis, and the symptoms all can be tolerated after symptomatic treatment. Conclusions: Oxycodone hydrochloride prolonged- release tablets per 12h to start titration are effective, convenient and rapid in titration of moderate and severe cancer pain.},
year = {2019}
}
TY - JOUR T1 - A Clinical Study of Oxycodone Hydrochloride Prolonged-release Tablets in the Titration of Cancer Pain AU - Guo Hui AU - Xu Huiqing Y1 - 2019/11/18 PY - 2019 T2 - Asia-Pacific Journal of Medicine JF - Asia-Pacific Journal of Medicine JO - Asia-Pacific Journal of Medicine SP - 28 EP - 31 PB - Science Publishing Group UR - http://www.sciencepg.com/article/10043464 AB - Objectives: To observe the efficacy and safety of oxycodone hydrochloride prolonged-release tablets in the titration of moderate and severe cancer pain. Methods: 80 outpatients with moderate and severe cancer pain treated with oxycodone hydrochloride prolonged-release tablets were divided into two groups: experimental group used oxycodone hydrochloride prolonged-release tablets per 12h to start titration, control group used oxycodone hydrochloride prolonged-release tablets per 24h to start titration. The effects and adverse effects of two group within 24 hours and 72 hours were observed and compared. Results: After 24hours of titration, pain-relieving objective response rate of experimental group was 75.00%, while control group was 52.50% with statistically significant differences (pp>0.05). The main adverse reactions of cancer pain patients were constipation, nausea and vomiting, abdominal distension, drowsiness, dizziness and anorexia apocleisis, and the symptoms all can be tolerated after symptomatic treatment. Conclusions: Oxycodone hydrochloride prolonged- release tablets per 12h to start titration are effective, convenient and rapid in titration of moderate and severe cancer pain. VL - 2 IS - 4 ER -
Information
Email: